# A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma

> **NCT00362102** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 38 (—)

## Conditions studied

- Colorectal Carcinoma

## Interventions

- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT00362102
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 38 (—)
- **Last updated:** 2016-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00362102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00362102, "A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00362102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*